personalized glp-1 and affordable weight loss telehealth plan Personalized GLP-1 – My Healthy

ELIXA trial included patients with recent cardiovascular event (patients with acute coronary syndrome 180 days before randomization), and although there was no benefit in MACE reduction in lixisenatide treated patients compared to placebo, results revealed cardiovascular safety of lixisenatide in this specific high risk population (38, 40)

69 SongS.GuoR.MehmoodA.ZhangL.YinB.YuanC.et al (2022)

SEMAGLUTIDE Semaglutide is a once-weekly GLP-1 medication designed to support healthy weight loss through personalized medical care

Nat Rev Cardiol 21(2):69 Kushner RF, Ryan DH, Deanfield J, Kokkinos A, Cercato C, Wilding J et al (2025) Safety profile of semaglutide versus placebo in the SELECT study: a randomized controlled trial

They claim the method is backed by science, endorsed by Harvard or Oxford, and used by celebrities